Study to Evaluate the Pharmacokinetics and Pharmacodynamics of AZD4604 Given Via the Turbuhaler® Device in Adults With Mild Asthma.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-27

Study Completion Date

2025-05-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will investigate the Pharmacokinetic (PK), Pharmacodynamic (PD), the safety and tolerability of AZD4604, as well as to examine the effect of Fractional exhaled Nitric Oxide (FeNO) following the administration of the multiple doses of AZD4604 via Turbuhaler device.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma

NCT01348139

Asthma

COMPLETED PHASE2

Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199

NCT00736489

Asthma Airway Obstruction

COMPLETED PHASE2

Study to Assess Effect of Device and Formulation on Pharmacokinetics (PK) of AZD1402

NCT03921268

Asthma

COMPLETED PHASE1

A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.

NCT04072562

Asthma

COMPLETED PHASE1

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

NCT03622112

Asthma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicentre, randomised, placebo-controlled, single-blind study to characterise PK and PD of AZD4604, administered twice daily (BID) using a Turbuhaler or a Genuair device.

Participants who have mild asthma with a raised FeNO will be randomised into the study to evaluate AZD4604 versus placebo, at 2 dose levels delivered via: a) the Turbuhaler device and b) the Genuair device.

The study will be comprised of:

* A screening period (Day -42 to Day-3)
* Participants will be randomised to one of 5 treatment arms where participants will either receive BID doses of AZD4604 or placebo from Day 1 to Day 9 and a single dose on Day 10.
* A follow-up Visit on Day 16

The total duration of the study will be for 58 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AZD4604 dose A via Genuair

Participants will receive dose A of AZD4604 via Genuair device twice daily

Group Type EXPERIMENTAL

AZD4604

Intervention Type DRUG

Participants will receive AZD4604 via Genuair/Turbuhaler device.

Genuair

Intervention Type DEVICE

Participants will either receive AZD4604 or placebo via Genuair device.

AZD4604 dose A via Turbuhaler

Participants will receive dose A of AZD4604 via Turbuhaler device twice daily

Group Type EXPERIMENTAL

AZD4604

Intervention Type DRUG

Participants will receive AZD4604 via Genuair/Turbuhaler device.

Turbuhaler

Intervention Type DEVICE

Participants will receive either AZD4604 or placebo via Turbuhaler device.

AZD4604 dose B via Turbuhaler

Participants will receive dose B of AZD4604 via Turbuhaler device twice daily

Group Type EXPERIMENTAL

AZD4604

Intervention Type DRUG

Participants will receive AZD4604 via Genuair/Turbuhaler device.

Turbuhaler

Intervention Type DEVICE

Participants will receive either AZD4604 or placebo via Turbuhaler device.

Placebo via Genuair

Participants will receive placebo via Genuair device twice daily

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Participants will receive placebo via Genuair/Turbuhaler device.

Genuair

Intervention Type DEVICE

Participants will either receive AZD4604 or placebo via Genuair device.

Placebo via Turbuhaler

Participants will receive placebo via Turbuhaler device twice daily

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Participants will receive placebo via Genuair/Turbuhaler device.

Turbuhaler

Intervention Type DEVICE

Participants will receive either AZD4604 or placebo via Turbuhaler device.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD4604

Participants will receive AZD4604 via Genuair/Turbuhaler device.

Intervention Type DRUG

Placebo

Participants will receive placebo via Genuair/Turbuhaler device.

Intervention Type OTHER

Genuair

Participants will either receive AZD4604 or placebo via Genuair device.

Intervention Type DEVICE

Turbuhaler

Participants will receive either AZD4604 or placebo via Turbuhaler device.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant must be 18 to 65 years of age inclusive with suitable veins for cannulation or repeated venepuncture.
* Participants must have Physician-diagnosed mild asthma for at least 6 months prior to Screening Visit.
* ≥ 70% predicted for FEV1 at the Screening Visit AND on Day -1.
* Have a FeNO of ≥ 40 ppb at the Screening Visit and on Day -2.
* Body weight at least 50 kg and BMI within the range 18 to 35 kg/m2 (inclusive).
* Female participants must have a negative pregnancy test at the Screening Visit and on admission to the clinical site or prior to randomisation and must not be lactating. However, there are no restrictions on male participants or their female partners.
* Contraceptive use by females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* Capable of giving signed and dated informed consent prior to any study-specific procedure.

Exclusion Criteria

* History of any clinically important disease or disorder which, in the opinion of the Principal Investigator (PI), may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
* History of cancer within the last 10 years (20 years for breast cancer) except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated and considered cured. Any history of lymphoma is not allowed and disease history suggesting abnormal immune function.
* Participants with increased risk of infection.
* Have received any vaccine in the 30 days prior to the first dose.
* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
* Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of the study intervention.
* History of serious or severe adverse reaction or known hypersensitivity to AZD4604 or any of its additive constituents
* High sensitivity C-reactive protein \> Upper Limit of Normal (ULN) at Screening Visit and Baseline/Run-in Period.
* Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results as judged by the PI. The PI may consider appropriate ethnicity adjusted local reference ranges for haematology or clinical chemistry measurements, when available.
* Known or suspected history of drug abuse as judged by the PI and current smokers.
* History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to AZD4604.
* Use of drugs with enzyme-inducing properties such as St John's wort within 3 weeks prior to the first administration of study intervention.
* History of alcohol abuse or excessive intake of alcohol as judged by the PI.
* Plasma donation within one month of the Screening Visit or any blood donation/blood loss \> 500 mL during the 3 months prior to the Screening Visit.
* Participants who cannot communicate reliably with the PI or vulnerable participants.
* Any clinically important abnormalities in rhythm, conduction or morphology of the resting Electrocardiogram (ECG) and any clinically important abnormalities in the 12-lead ECG as considered by the investigator that may interfere with the interpretation of QTc interval changes.
* Female participants who are planning a pregnancy during the study period or within one month after the last dose of study intervention.
* Exacerbation of asthma symptoms within 6 months prior to Screening Visit and Day -1 requiring the use of oral, IM or IV steroids, antibiotics, accident and emergency visit, or hospital admission.
* If in the judgement of the PI, the participant has any ongoing or recent (ie, during the Screening Period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements, the participant should not be enrolled.
* Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of study intervention in this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No